NDAINTRAVENOUSSOLUTION
Approved
Apr 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
MOXIFLOXACIN HYDROCHLORIDE (moxifloxacin hydrochloride) by Fresenius Kabi is [see microbiology ()]. Approved for bacterial infections, community-acquired pneumonia, copd exacerbation and 2 more indications. First approved in 2015.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Moxifloxacin hydrochloride is a fourth-generation fluoroquinolone antibiotic administered intravenously to treat serious bacterial infections including community-acquired pneumonia, COPD exacerbation, and bacterial conjunctivitis. It works by inhibiting bacterial DNA gyrase, preventing DNA replication and cell survival.
Peak
Product is at peak commercial stage under Fresenius Kabi ownership with moderate competitive pressure (30/100), indicating stable demand and mid-sized commercial infrastructure.
Mechanism of Action
[see Microbiology ()].
Worked on MOXIFLOXACIN HYDROCHLORIDE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.